Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-01-18 Call Transcript
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter from the company to stock exchanges announcing an upcoming earnings conference call scheduled for February 14, 2024, to discuss financial performance for the quarter and nine months ended December 31, 2023. It includes dial-in details and mentions that the transcript and audio recording will be made available on the company's website. The document does not contain actual financial results or substantive financial data but is an announcement of the call event. Therefore, it is not an Earnings Release (ER) or Interim Report (IR) but rather a Call Transcript (CT) announcement. However, since the transcript is not included and only the call announcement is provided, the best fit is Call Transcript (CT) as it relates to the earnings call event.
2024-01-18 English
Board Meeting — GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 14-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the…
Regulatory Filings
2024-01-11 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for February 14, 2024, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2023. It also mentions the trading window closure and reopening dates and announces an earnings call on the same day. The document does not contain the financial results themselves but informs about the meeting and related events. The length is short (1872 characters), and it serves as an announcement rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the board meeting and earnings call, not the actual financial report or earnings release.
2024-01-11 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a short letter addressed to stock exchanges regarding a certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018. It references a Confirmation Certificate from the Registrar and Share Transfer Agent for the quarter ended December 31, 2023. The document is only 1211 characters long and does not contain any financial data or detailed report content. It is primarily a regulatory compliance communication providing a certificate for information and records. According to the rules, such short regulatory compliance communications or certifications should be classified as Regulatory Filings (RNS).
2024-01-11 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window due to insider trading regulations. It mentions the upcoming declaration of unaudited financial results for a specific quarter and nine months period but does not contain any financial data or results itself. The document is short (1452 characters) and serves as a notification rather than a report. Therefore, it is an announcement related to regulatory compliance and trading restrictions, fitting best under Regulatory Filings (RNS).
2023-12-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a short notice dated December 7, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references compliance with SEBI Listing Obligations and Disclosure Requirements. The content is an announcement of a meeting schedule, not a report or transcript of the meeting itself. The document length is only 1524 characters, indicating it is a brief announcement rather than a detailed report or transcript. Therefore, it fits the category of Investor Presentation announcements or meeting schedule notifications. Since it is specifically about scheduling an analyst/investor meeting, the best fitting category is Investor Presentation (IP).
2023-12-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.